Clinical Trial Update: Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA) [Phase 1]

View source ↗

Summary

Phase 1 study reports ascending-dose pharmacokinetics and absolute bioavailability for an antibiotic developed by Trius Therapeutics (a Merck subsidiary).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infections

Snippet

Sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Bacterial Infections | Phase 1 | Status: COMPLETED